Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer (NSCLC) …

… Prior to the development of epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) … The aim of the present retrospective cohort study was to determine the real-world …

… To reduce the selection bias inherent to retrospective cohort studies, we conducted
propensity score matching to control for potential confounders [34]. Baseline characteristics, …

… Study Design In a retrospective cohort study, we assessed the effect of tki availability on
outcomes in patients diagnosed with metastatic gist in British Columbia between 1996 and 2016…

… To our knowledge, this is one of the largest cohort studies from Western Europe reporting
real-world treatment effects of first-, second- and third-generation TKI, stratifying between …

… factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are … exists on efficacy of EGFR TKIs
in European patient cohorts. … from eight randomised studies and 82 cohort studies (HR 0.99…

… Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in patients with …
of fatigue and its relationship with physical activity. In this study, 220 CML patients receiving TKI …

… The objectives of this study were to evaluate the plasma concentrations of the tyrosine
kinase inhibitors (TKIs), imatinib, erlotinib, and sunitinib, in a cohort of patients with cancer in …

… The results described in this study will serve as reference to interpret the potential benefit
of adding tyrosine-kinase inhibitors to the first-line treatment regimens of children with ABL-…

… of BCR-ABL tyrosine kinase inhibitors (TKI), … studies suggest a significant impact of
haematologic malignancies and their treatment on patients’ employment. A Danish cohort study of …